EMEA (Europe, Middle East and Africa) Hematological Malignancies Disease Market Report 2017

October 2017 | 117 pages | ID: E73B8E7AA20PEN
QYResearch

Abstracts

In this report, the EMEA Hematological Malignancies Disease market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Units), revenue (Million USD), market share and growth rate of Hematological Malignancies Disease for these regions, from 2012 to 2022 (forecast)

• Europe: Germany, France, UK, Russia, Italy and Benelux;
• Middle East: Saudi Arabia, Israel, UAE and Iran;
• Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA Hematological Malignancies Disease market competition by top manufacturers/players, with Hematological Malignancies Disease sales volume (K Units), price (USD/Unit), revenue (Million USD) and market share for each manufacturer/player; the top players including

• Affymetrix
• SkylineDx
• AgenaBio
• Signal Genetics
• Cancer Genetics Inc
• Illumina
• NeoGenomics
• Exiqon
• Regulus Therapeutics
• Rosetta Genomics
• Sequenta
• Takeda Pharma
• Celgene
• Amgen
• Ono Pharma
• Abbott
• BMS
• Mundipharma
• Novartis
• MorphoSys

On the basis of product, this report displays the sales volume (K Units), revenue (Million USD), product price (USD/Unit), market share and growth rate of each type, primarily split into

• Chemotherapy
• Immunotherapy
• Targeted Therapy

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume (K Units), market share and growth rate of Hematological Malignancies Disease for each application, including

• Leukemia
• Lymphoma
• Myeloma

If you have any special requirements, please let us know and we will offer you the report as you want.

Contents

EMEA (Europe, Middle East and Africa) Hematological Malignancies Disease Market Report 2017

1 HEMATOLOGICAL MALIGNANCIES DISEASE OVERVIEW

1.1 Product Overview and Scope of Hematological Malignancies Disease
1.2 Classification of Hematological Malignancies Disease
  1.2.1 EMEA Hematological Malignancies Disease Market Size (Sales) Comparison by Type (2012-2022)
  1.2.2 EMEA Hematological Malignancies Disease Market Size (Sales) Market Share by Type (Product Category) in 2016
  1.2.3 Chemotherapy
  1.2.4 Immunotherapy
  1.2.5 Targeted Therapy
1.3 EMEA Hematological Malignancies Disease Market by Application/End Users
  1.3.1 EMEA Hematological Malignancies Disease Sales (Volume) and Market Share Comparison by Application (2012-2022
  1.3.2 Leukemia
  1.3.3 Lymphoma
  1.3.4 Myeloma
1.4 EMEA Hematological Malignancies Disease Market by Region
  1.4.1 EMEA Hematological Malignancies Disease Market Size (Value) Comparison by Region (2012-2022)
  1.4.2 Europe Status and Prospect (2012-2022)
  1.4.3 Middle East Status and Prospect (2012-2022)
  1.4.4 Africa Status and Prospect (2012-2022)
1.5 EMEA Market Size (Value and Volume) of Hematological Malignancies Disease (2012-2022)
  1.5.1 EMEA Hematological Malignancies Disease Sales and Growth Rate (2012-2022)
  1.5.2 EMEA Hematological Malignancies Disease Revenue and Growth Rate (2012-2022)

2 EMEA HEMATOLOGICAL MALIGNANCIES DISEASE COMPETITION BY MANUFACTURERS/PLAYERS/SUPPLIERS, REGION, TYPE AND APPLICATION

2.1 EMEA Hematological Malignancies Disease Market Competition by Players/Manufacturers
  2.1.1 EMEA Hematological Malignancies Disease Sales Volume and Market Share of Major Players (2012-2017)
  2.1.2 EMEA Hematological Malignancies Disease Revenue and Share by Players (2012-2017)
  2.1.3 EMEA Hematological Malignancies Disease Sale Price by Players (2012-2017)
2.2 EMEA Hematological Malignancies Disease (Volume and Value) by Type/Product Category
  2.2.1 EMEA Hematological Malignancies Disease Sales and Market Share by Type (2012-2017)
  2.2.2 EMEA Hematological Malignancies Disease Revenue and Market Share by Type (2012-2017)
  2.2.3 EMEA Hematological Malignancies Disease Sale Price by Type (2012-2017)
2.3 EMEA Hematological Malignancies Disease (Volume) by Application
2.4 EMEA Hematological Malignancies Disease (Volume and Value) by Region
  2.4.1 EMEA Hematological Malignancies Disease Sales and Market Share by Region (2012-2017)
  2.4.2 EMEA Hematological Malignancies Disease Revenue and Market Share by Region (2012-2017)
  2.4.3 EMEA Hematological Malignancies Disease Sales Price by Region (2012-2017)

3 EUROPE HEMATOLOGICAL MALIGNANCIES DISEASE (VOLUME, VALUE AND SALES PRICE), BY PLAYERS, COUNTRIES, TYPE AND APPLICATION

3.1 Europe Hematological Malignancies Disease Sales and Value (2012-2017)
  3.1.1 Europe Hematological Malignancies Disease Sales Volume and Growth Rate (2012-2017)
  3.1.2 Europe Hematological Malignancies Disease Revenue and Growth Rate (2012-2017)
3.2 Europe Hematological Malignancies Disease Sales and Market Share by Type
3.3 Europe Hematological Malignancies Disease Sales and Market Share by Application
3.4 Europe Hematological Malignancies Disease Sales Volume and Value (Revenue) by Countries
  3.4.1 Europe Hematological Malignancies Disease Sales Volume by Countries (2012-2017)
  3.4.2 Europe Hematological Malignancies Disease Revenue by Countries (2012-2017)
  3.4.3 Germany Hematological Malignancies Disease Sales and Growth Rate (2012-2017)
  3.4.4 France Hematological Malignancies Disease Sales and Growth Rate (2012-2017)
  3.4.5 UK Hematological Malignancies Disease Sales and Growth Rate (2012-2017)
  3.4.6 Russia Hematological Malignancies Disease Sales and Growth Rate (2012-2017)
  3.4.7 Italy Hematological Malignancies Disease Sales and Growth Rate (2012-2017)
  3.4.8 Benelux Hematological Malignancies Disease Sales and Growth Rate (2012-2017)

4 MIDDLE EAST HEMATOLOGICAL MALIGNANCIES DISEASE (VOLUME, VALUE AND SALES PRICE), BY REGION, TYPE AND APPLICATION

4.1 Middle East Hematological Malignancies Disease Sales and Value (2012-2017)
  4.1.1 Middle East Hematological Malignancies Disease Sales Volume and Growth Rate (2012-2017)
  4.1.2 Middle East Hematological Malignancies Disease Revenue and Growth Rate (2012-2017)
4.2 Middle East Hematological Malignancies Disease Sales and Market Share by Type
4.3 Middle East Hematological Malignancies Disease Sales and Market Share by Application
4.4 Middle East Hematological Malignancies Disease Sales Volume and Value (Revenue) by Countries
  4.4.1 Middle East Hematological Malignancies Disease Sales Volume by Countries (2012-2017)
  4.4.2 Middle East Hematological Malignancies Disease Revenue by Countries (2012-2017)
  4.4.3 Saudi Arabia Hematological Malignancies Disease Sales and Growth Rate (2012-2017)
  4.4.4 Israel Hematological Malignancies Disease Sales and Growth Rate (2012-2017)
  4.4.5 UAE Hematological Malignancies Disease Sales and Growth Rate (2012-2017)
  4.4.6 Iran Hematological Malignancies Disease Sales and Growth Rate (2012-2017)

5 AFRICA HEMATOLOGICAL MALIGNANCIES DISEASE (VOLUME, VALUE AND SALES PRICE) BY PLAYERS, COUNTRIES, TYPE AND APPLICATION

5.1 Africa Hematological Malignancies Disease Sales and Value (2012-2017)
  5.1.1 Africa Hematological Malignancies Disease Sales Volume and Growth Rate (2012-2017)
  5.1.2 Africa Hematological Malignancies Disease Revenue and Growth Rate (2012-2017)
5.2 Africa Hematological Malignancies Disease Sales and Market Share by Type
5.3 Africa Hematological Malignancies Disease Sales and Market Share by Application
5.4 Africa Hematological Malignancies Disease Sales Volume and Value (Revenue) by Countries
  5.4.1 Africa Hematological Malignancies Disease Sales Volume by Countries (2012-2017)
  5.4.2 Africa Hematological Malignancies Disease Revenue by Countries (2012-2017)
  5.4.3 South Africa Hematological Malignancies Disease Sales and Growth Rate (2012-2017)
  5.4.4 Nigeria Hematological Malignancies Disease Sales and Growth Rate (2012-2017)
  5.4.5 Egypt Hematological Malignancies Disease Sales and Growth Rate (2012-2017)
  5.4.6 Algeria Hematological Malignancies Disease Sales and Growth Rate (2012-2017)

6 EMEA HEMATOLOGICAL MALIGNANCIES DISEASE MANUFACTURERS/PLAYERS PROFILES AND SALES DATA

6.1 Affymetrix
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Hematological Malignancies Disease Product Type, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 Affymetrix Hematological Malignancies Disease Sales, Revenue, Price and Gross Margin (2012-2017)
  6.1.4 Main Business/Business Overview
6.2 SkylineDx
  6.2.1 Company Basic Information, Manufacturing Base and Competitors
  6.2.2 Hematological Malignancies Disease Product Type, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 SkylineDx Hematological Malignancies Disease Sales, Revenue, Price and Gross Margin (2012-2017)
  6.2.4 Main Business/Business Overview
6.3 AgenaBio
  6.3.1 Company Basic Information, Manufacturing Base and Competitors
  6.3.2 Hematological Malignancies Disease Product Type, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 AgenaBio Hematological Malignancies Disease Sales, Revenue, Price and Gross Margin (2012-2017)
  6.3.4 Main Business/Business Overview
6.4 Signal Genetics
  6.4.1 Company Basic Information, Manufacturing Base and Competitors
  6.4.2 Hematological Malignancies Disease Product Type, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 Signal Genetics Hematological Malignancies Disease Sales, Revenue, Price and Gross Margin (2012-2017)
  6.4.4 Main Business/Business Overview
6.5 Cancer Genetics Inc
  6.5.1 Company Basic Information, Manufacturing Base and Competitors
  6.5.2 Hematological Malignancies Disease Product Type, Application and Specification
    6.5.2.1 Product A
    6.5.2.2 Product B
  6.5.3 Cancer Genetics Inc Hematological Malignancies Disease Sales, Revenue, Price and Gross Margin (2012-2017)
  6.5.4 Main Business/Business Overview
6.6 Illumina
  6.6.1 Company Basic Information, Manufacturing Base and Competitors
  6.6.2 Hematological Malignancies Disease Product Type, Application and Specification
    6.6.2.1 Product A
    6.6.2.2 Product B
  6.6.3 Illumina Hematological Malignancies Disease Sales, Revenue, Price and Gross Margin (2012-2017)
  6.6.4 Main Business/Business Overview
6.7 NeoGenomics
  6.7.1 Company Basic Information, Manufacturing Base and Competitors
  6.7.2 Hematological Malignancies Disease Product Type, Application and Specification
    6.7.2.1 Product A
    6.7.2.2 Product B
  6.7.3 NeoGenomics Hematological Malignancies Disease Sales, Revenue, Price and Gross Margin (2012-2017)
  6.7.4 Main Business/Business Overview
6.8 Exiqon
  6.8.1 Company Basic Information, Manufacturing Base and Competitors
  6.8.2 Hematological Malignancies Disease Product Type, Application and Specification
    6.8.2.1 Product A
    6.8.2.2 Product B
  6.8.3 Exiqon Hematological Malignancies Disease Sales, Revenue, Price and Gross Margin (2012-2017)
  6.8.4 Main Business/Business Overview
6.9 Regulus Therapeutics
  6.9.1 Company Basic Information, Manufacturing Base and Competitors
  6.9.2 Hematological Malignancies Disease Product Type, Application and Specification
    6.9.2.1 Product A
    6.9.2.2 Product B
  6.9.3 Regulus Therapeutics Hematological Malignancies Disease Sales, Revenue, Price and Gross Margin (2012-2017)
  6.9.4 Main Business/Business Overview
6.10 Rosetta Genomics
  6.10.1 Company Basic Information, Manufacturing Base and Competitors
  6.10.2 Hematological Malignancies Disease Product Type, Application and Specification
    6.10.2.1 Product A
    6.10.2.2 Product B
  6.10.3 Rosetta Genomics Hematological Malignancies Disease Sales, Revenue, Price and Gross Margin (2012-2017)
  6.10.4 Main Business/Business Overview
6.11 Sequenta
6.12 Takeda Pharma
6.13 Celgene
6.14 Amgen
6.15 Ono Pharma
6.16 Abbott
6.17 BMS
6.18 Mundipharma
6.19 Novartis
6.20 MorphoSys

7 HEMATOLOGICAL MALIGNANCIES DISEASE MANUFACTURING COST ANALYSIS

7.1 Hematological Malignancies Disease Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Hematological Malignancies Disease

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Hematological Malignancies Disease Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Hematological Malignancies Disease Major Manufacturers in 2016
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 EMEA HEMATOLOGICAL MALIGNANCIES DISEASE MARKET FORECAST (2017-2022)

11.1 EMEA Hematological Malignancies Disease Sales, Revenue and Price Forecast (2017-2022)
  11.1.1 EMEA Hematological Malignancies Disease Sales and Growth Rate Forecast (2017-2022)
  11.1.2 EMEA Hematological Malignancies Disease Revenue and Growth Rate Forecast (2017-2022)
  11.1.3 EMEA Hematological Malignancies Disease Price and Trend Forecast (2017-2022)
11.2 EMEA Hematological Malignancies Disease Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.3 Europe Hematological Malignancies Disease Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.4 Middle Eastt Hematological Malignancies Disease Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.5 Africa Hematological Malignancies Disease Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.6 EMEA Hematological Malignancies Disease Sales Forecast by Type (2017-2022)
11.7 EMEA Hematological Malignancies Disease Sales Forecast by Application (2017-2022)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer


The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Product Picture of Hematological Malignancies Disease
Figure EMEA Hematological Malignancies Disease Sales Volume (K Units) by Type (2012-2022)
Figure EMEA Hematological Malignancies Disease Sales Volume Market Share by Type (Product Category) in 2016
Figure Chemotherapy Product Picture
Figure Immunotherapy Product Picture
Figure Targeted Therapy Product Picture
Figure EMEA Hematological Malignancies Disease Sales Volume (K Units) by Application (2012-2022)
Figure EMEA Sales Market Share of Hematological Malignancies Disease by Application in 2016
Figure Leukemia Examples
Figure Lymphoma Examples
Figure Myeloma Examples
Figure EMEA Hematological Malignancies Disease Market Size (Million USD) by Region (2012-2022)
Figure Europe Hematological Malignancies Disease Revenue (Million USD) and Growth Rate (2012-2022)
Figure Europe Hematological Malignancies Disease Revenue (Million USD) Status and Forecast by Countries
Figure Middle East Hematological Malignancies Disease Revenue (Million USD) and Growth Rate (2012-2022)
Figure Middle East Hematological Malignancies Disease Revenue (Million USD) Status and Forecast by Countries
Figure Africa Hematological Malignancies Disease Revenue (Million USD) and Growth Rate (2012-2022)
Figure Africa Hematological Malignancies Disease Revenue (Million USD) Status and Forecast by Countries
Figure EMEA Hematological Malignancies Disease Sales Volume and Growth Rate (2012-2022)
Figure EMEA Hematological Malignancies Disease Revenue (Million USD) and Growth Rate (2012-2022)
Figure EMEA Hematological Malignancies Disease Market Major Players Product Sales Volume (K Units) (2012-2017)
Table EMEA Hematological Malignancies Disease Sales Volume (K Units) of Major Players (2012-2017)
Table EMEA Hematological Malignancies Disease Sales Share by Players (2012-2017)
Figure 2016 Hematological Malignancies Disease Sales Share by Players
Figure 2017 Hematological Malignancies Disease Sales Share by Players
Figure EMEA Hematological Malignancies Disease Market Major Players Product Revenue (Million USD) (2012-2017)
Table EMEA Hematological Malignancies Disease Revenue (Million USD) by Players (2012-2017)
Table EMEA Hematological Malignancies Disease Revenue Share by Players (2012-2017)
Table 2016 EMEA Hematological Malignancies Disease Revenue Share by Players
Table 2017 EMEA Hematological Malignancies Disease Revenue Share by Players
Table EMEA Hematological Malignancies Disease Sale Price (USD/Unit) by Players (2012-2017)
Table EMEA Hematological Malignancies Disease Sales (K Units) and Market Share by Type (2012-2017)
Table EMEA Hematological Malignancies Disease Sales Share by Type (2012-2017)
Figure Sales Market Share of Hematological Malignancies Disease by Type (2012-2017)
Figure EMEA Hematological Malignancies Disease Sales Market Share by Type (2012-2017)
Table EMEA Hematological Malignancies Disease Revenue (Million USD) and Market Share by Type (2012-2017)
Table EMEA Hematological Malignancies Disease Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Hematological Malignancies Disease by Type in 2016
Table EMEA Hematological Malignancies Disease Sale Price (USD/Unit) by Type (2012-2017)
Table EMEA Hematological Malignancies Disease Sales (K Units) and Market Share by Application (2012-2017)
Table EMEA Hematological Malignancies Disease Sales Share by Application (2012-2017)
Figure Sales Market Share of Hematological Malignancies Disease by Application (2012-2017)
Figure EMEA Hematological Malignancies Disease Sales Market Share by Application in 2016
Table EMEA Hematological Malignancies Disease Sales (K Units) and Market Share by Region (2012-2017)
Table EMEA Hematological Malignancies Disease Sales Share by Region (2012-2017)
Figure Sales Market Share of Hematological Malignancies Disease by Region (2012-2017)
Figure EMEA Hematological Malignancies Disease Sales Market Share in 2016
Table EMEA Hematological Malignancies Disease Revenue (Million USD) and Market Share by Region (2012-2017)
Table EMEA Hematological Malignancies Disease Revenue Share by Region (2012-2017)
Figure Revenue Market Share of Hematological Malignancies Disease by Region (2012-2017)
Figure EMEA Hematological Malignancies Disease Revenue Market Share Regions in 2016
Table EMEA Hematological Malignancies Disease Sales Price (USD/Unit) by Region (2012-2017)
Figure Europe Hematological Malignancies Disease Sales (K Units) and Growth Rate (2012-2017)
Figure Europe Hematological Malignancies Disease Revenue and Growth Rate (2012-2017)
Table Europe Hematological Malignancies Disease Sales (K Units) by Type (2012-2017)
Table Europe Hematological Malignancies Disease Market Share by Type (2012-2017)
Figure Europe Hematological Malignancies Disease Market Share by Type in 2016
Table Europe Hematological Malignancies Disease Sales (K Units) by Application (2012-2017)
Table Europe Hematological Malignancies Disease Market Share by Application (2012-2017)
Figure Europe Hematological Malignancies Disease Market Share by Application in 2016
Table Europe Hematological Malignancies Disease Sales (K Units) by Countries (2012-2017)
Table Europe Hematological Malignancies Disease Sales Market Share by Countries (2012-2017)
Figure Europe Hematological Malignancies Disease Sales Market Share by Countries (2012-2017)
Figure Europe Hematological Malignancies Disease Sales Market Share by Countries in 2016
Table Europe Hematological Malignancies Disease Revenue (Million USD) by Countries (2012-2017)
Table Europe Hematological Malignancies Disease Revenue Market Share by Countries (2012-2017)
Figure Europe Hematological Malignancies Disease Revenue Market Share by Countries (2012-2017)
Figure Europe Hematological Malignancies Disease Revenue Market Share by Countries in 2016
Figure Germany Hematological Malignancies Disease Sales (K Units) and Growth Rate (2012-2017)
Figure France Hematological Malignancies Disease Sales (K Units) and Growth Rate (2012-2017)
Figure UK Hematological Malignancies Disease Sales (K Units) and Growth Rate (2012-2017)
Figure Russia Hematological Malignancies Disease Sales (K Units) and Growth Rate (2012-2017)
Figure Italy Hematological Malignancies Disease Sales (K Units) and Growth Rate (2012-2017)
Figure Benelux Hematological Malignancies Disease Sales (K Units) and Growth Rate (2012-2017)
Figure Middle East Hematological Malignancies Disease Sales (K Units) and Growth Rate (2012-2017)
Figure Middle East Hematological Malignancies Disease Revenue (Million USD) and Growth Rate (2012-2017)
Table Middle East Hematological Malignancies Disease Sales (K Units) by Type (2012-2017)
Table Middle East Hematological Malignancies Disease Market Share by Type (2012-2017)
Figure Middle East Hematological Malignancies Disease Market Share by Type (2012-2017)
Table Middle East Hematological Malignancies Disease Sales (K Units) by Applications (2012-2017)
Table Middle East Hematological Malignancies Disease Market Share by Applications (2012-2017)
Figure Middle East Hematological Malignancies Disease Sales Market Share by Application in 2016
Table Middle East Hematological Malignancies Disease Sales Volume (K Units) by Countries (2012-2017)
Table Middle East Hematological Malignancies Disease Sales Volume Market Share by Countries (2012-2017)
Figure Middle East Hematological Malignancies Disease Sales Volume Market Share by Countries in 2016
Table Middle East Hematological Malignancies Disease Revenue (Million USD) by Countries (2012-2017)
Table Middle East Hematological Malignancies Disease Revenue Market Share by Countries (2012-2017)
Figure Middle East Hematological Malignancies Disease Revenue Market Share by Countries (2012-2017)
Figure Middle East Hematological Malignancies Disease Revenue Market Share by Countries in 2016
Figure Saudi Arabia Hematological Malignancies Disease Sales (K Units) and Growth Rate (2012-2017)
Figure Israel Hematological Malignancies Disease Sales (K Units) and Growth Rate (2012-2017)
Figure UAE Hematological Malignancies Disease Sales (K Units) and Growth Rate (2012-2017)
Figure Iran Hematological Malignancies Disease Sales (K Units) and Growth Rate (2012-2017)
Figure Africa Hematological Malignancies Disease Sales (K Units) and Growth Rate (2012-2017)
Figure Africa Hematological Malignancies Disease Revenue (Million USD) and Growth Rate (2012-2017)
Table Africa Hematological Malignancies Disease Sales (K Units) by Type (2012-2017)
Table Africa Hematological Malignancies Disease Sales Market Share by Type (2012-2017)
Figure Africa Hematological Malignancies Disease Sales Market Share by Type (2012-2017)
Figure Africa Hematological Malignancies Disease Sales Market Share by Type in 2016
Table Africa Hematological Malignancies Disease Sales (K Units) by Application (2012-2017)
Table Africa Hematological Malignancies Disease Sales Market Share by Application (2012-2017)
Figure Africa Hematological Malignancies Disease Sales Market Share by Application (2012-2017)
Table Africa Hematological Malignancies Disease Sales Volume (K Units) by Countries (2012-2017)
Table Africa Hematological Malignancies Disease Sales Market Share by Countries (2012-2017)
Figure Africa Hematological Malignancies Disease Sales Market Share by Countries (2012-2017)
Figure Africa Hematological Malignancies Disease Sales Market Share by Countries in 2016
Table Africa Hematological Malignancies Disease Revenue (Million USD) by Countries (2012-2017)
Table Africa Hematological Malignancies Disease Revenue Market Share by Countries (2012-2017)
Figure Africa Hematological Malignancies Disease Revenue Market Share by Countries (2012-2017)
Figure Africa Hematological Malignancies Disease Revenue Market Share by Countries in 2016
Figure South Africa Hematological Malignancies Disease Sales (K Units) and Growth Rate (2012-2017)
Figure Nigeria Hematological Malignancies Disease Sales (K Units) and Growth Rate (2012-2017)
Figure Egypt Hematological Malignancies Disease Sales (K Units) and Growth Rate (2012-2017)
Figure Algeria Hematological Malignancies Disease Sales (K Units) and Growth Rate (2012-2017)
Table Affymetrix Hematological Malignancies Disease Basic Information List
Table Affymetrix Hematological Malignancies Disease Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Affymetrix Hematological Malignancies Disease Sales (K Units) and Growth Rate (2012-2017)
Figure Affymetrix Hematological Malignancies Disease Sales Market Share in EMEA (2012-2017)
Figure Affymetrix Hematological Malignancies Disease Revenue Market Share in EMEA (2012-2017)
Table SkylineDx Hematological Malignancies Disease Basic Information List
Table SkylineDx Hematological Malignancies Disease Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure SkylineDx Hematological Malignancies Disease Sales (K Units) and Growth Rate (2012-2017)
Figure SkylineDx Hematological Malignancies Disease Sales Market Share in EMEA (2012-2017)
Figure SkylineDx Hematological Malignancies Disease Revenue Market Share in EMEA (2012-2017)
Table AgenaBio Hematological Malignancies Disease Basic Information List
Table AgenaBio Hematological Malignancies Disease Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure AgenaBio Hematological Malignancies Disease Sales (K Units) and Growth Rate (2012-2017)
Figure AgenaBio Hematological Malignancies Disease Sales Market Share in EMEA (2012-2017)
Figure AgenaBio Hematological Malignancies Disease Revenue Market Share in EMEA (2012-2017)
Table Signal Genetics Hematological Malignancies Disease Basic Information List
Table Signal Genetics Hematological Malignancies Disease Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Signal Genetics Hematological Malignancies Disease Sales (K Units) and Growth Rate (2012-2017)
Figure Signal Genetics Hematological Malignancies Disease Sales Market Share in EMEA (2012-2017)
Figure Signal Genetics Hematological Malignancies Disease Revenue Market Share in EMEA (2012-2017)
Table Cancer Genetics Inc Hematological Malignancies Disease Basic Information List
Table Cancer Genetics Inc Hematological Malignancies Disease Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Cancer Genetics Inc Hematological Malignancies Disease Sales (K Units) and Growth Rate (2012-2017)
Figure Cancer Genetics Inc Hematological Malignancies Disease Sales Market Share in EMEA (2012-2017)
Figure Cancer Genetics Inc Hematological Malignancies Disease Revenue Market Share in EMEA (2012-2017)
Table Illumina Hematological Malignancies Disease Basic Information List
Table Illumina Hematological Malignancies Disease Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Illumina Hematological Malignancies Disease Sales (K Units) and Growth Rate (2012-2017)
Figure Illumina Hematological Malignancies Disease Sales Market Share in EMEA (2012-2017)
Figure Illumina Hematological Malignancies Disease Revenue Market Share in EMEA (2012-2017)
Table NeoGenomics Hematological Malignancies Disease Basic Information List
Table NeoGenomics Hematological Malignancies Disease Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure NeoGenomics Hematological Malignancies Disease Sales (K Units) and Growth Rate (2012-2017)
Figure NeoGenomics Hematological Malignancies Disease Sales Market Share in EMEA (2012-2017)
Figure NeoGenomics Hematological Malignancies Disease Revenue Market Share in EMEA (2012-2017)
Table Exiqon Hematological Malignancies Disease Basic Information List
Table Exiqon Hematological Malignancies Disease Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Exiqon Hematological Malignancies Disease Sales (K Units) and Growth Rate (2012-2017)
Figure Exiqon Hematological Malignancies Disease Sales Market Share in EMEA (2012-2017)
Figure Exiqon Hematological Malignancies Disease Revenue Market Share in EMEA (2012-2017)
Table Regulus Therapeutics Hematological Malignancies Disease Basic Information List
Table Regulus Therapeutics Hematological Malignancies Disease Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Regulus Therapeutics Hematological Malignancies Disease Sales (K Units) and Growth Rate (2012-2017)
Figure Regulus Therapeutics Hematological Malignancies Disease Sales Market Share in EMEA (2012-2017)
Figure Regulus Therapeutics Hematological Malignancies Disease Revenue Market Share in EMEA (2012-2017)
Table Rosetta Genomics Hematological Malignancies Disease Basic Information List
Table Rosetta Genomics Hematological Malignancies Disease Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Rosetta Genomics Hematological Malignancies Disease Sales (K Units) and Growth Rate (2012-2017)
Figure Rosetta Genomics Hematological Malignancies Disease Sales Market Share in EMEA (2012-2017)
Figure Rosetta Genomics Hematological Malignancies Disease Revenue Market Share in EMEA (2012-2017)
Table Sequenta Hematological Malignancies Disease Basic Information List
Table Takeda Pharma Hematological Malignancies Disease Basic Information List
Table Celgene Hematological Malignancies Disease Basic Information List
Table Amgen Hematological Malignancies Disease Basic Information List
Table Ono Pharma Hematological Malignancies Disease Basic Information List
Table Abbott Hematological Malignancies Disease Basic Information List
Table BMS Hematological Malignancies Disease Basic Information List
Table Mundipharma Hematological Malignancies Disease Basic Information List
Table Novartis Hematological Malignancies Disease Basic Information List
Table MorphoSys Hematological Malignancies Disease Basic Information List
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Hematological Malignancies Disease
Figure Manufacturing Process Analysis of Hematological Malignancies Disease
Figure Hematological Malignancies Disease Industrial Chain Analysis
Table Raw Materials Sources of Hematological Malignancies Disease Major Manufacturers in 2016
Table Major Buyers of Hematological Malignancies Disease
Table Distributors/Traders List
Figure EMEA Hematological Malignancies Disease Sales (K Units) and Growth Rate Forecast (2017-2022)
Figure EMEA Hematological Malignancies Disease Revenue and Growth Rate Forecast (2017-2022)
Figure EMEA Hematological Malignancies Disease Price (USD/Unit) and Trend Forecast (2017-2022)
Table EMEA Hematological Malignancies Disease Sales (K Units) Forecast by Region (2017-2022)
Figure EMEA Hematological Malignancies Disease Sales Market Share Forecast by Region (2017-2022)
Table EMEA Hematological Malignancies Disease Revenue (Million USD) Forecast by Region (2017-2022)
Figure EMEA Hematological Malignancies Disease Revenue Market Share Forecast by Region (2017-2022)
Table Europe Hematological Malignancies Disease Sales (K Units) Forecast by Countries (2017-2022)
Figure Europe Hematological Malignancies Disease Sales Market Share Forecast by Countries (2017-2022)
Table Europe Hematological Malignancies Disease Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Europe Hematological Malignancies Disease Revenue Market Share Forecast by Countries (2017-2022)
Table Middle East Hematological Malignancies Disease Sales (K Units) Forecast by Countries (2017-2022)
Figure Middle East Hematological Malignancies Disease Sales Market Share Forecast by Countries (2017-2022)
Table Middle East Hematological Malignancies Disease Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Middle East Hematological Malignancies Disease Revenue Market Share Forecast by Countries (2017-2022)
Table Africa Hematological Malignancies Disease Sales (K Units) Forecast by Countries (2017-2022)
Figure Africa Hematological Malignancies Disease Sales Market Share Forecast by Countries (2017-2022)
Table Africa Hematological Malignancies Disease Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Africa Hematological Malignancies Disease Revenue Market Share Forecast by Countries (2017-2022)
Table EMEA Hematological Malignancies Disease Sales (K Units) Forecast by Type (2017-2022)
Figure EMEA Hematological Malignancies Disease Sales Market Share Forecast by Type (2017-2022)
Table EMEA Hematological Malignancies Disease Sales (K Units) Forecast by Application (2017-2022)
Figure EMEA Hematological Malignancies Disease Sales Market Share Forecast by Application (2017-2022)
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources